Celltrion, Inc.
068270
शेयरों में रैंक
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
शेयर मूल्य
$146.63
मार्केट कैप
$33.44B
बदलाव (1 दिन)
-1.52%
बदलाव (1 वर्ष)
23.60%
देश
KR
व्यापार Celltrion, Inc. (068270)
श्रेणी
Healthcare
Celltrion, Inc. (068270) के लिए बकाया शेयरों की संख्या
June 2026 की स्थिति में बकाया शेयरों की संख्या: 233.25M
Celltrion, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी के वर्तमान बकाया शेयरों की संख्या 233.25M है। December 2024 के अंत में कंपनी के पास 217.00M बकाया शेयर थे। बकाया शेयरों की संख्या आमतौर पर शेयर स्प्लिट्स और शेयर बायबैक से प्रभावित होती है।
Celltrion, Inc. (068270) के लिए 2007 से 2026 तक बकाया शेयरों का इतिहास
प्रत्येक वर्ष के अंत में बकाया शेयर
| वर्ष | बकाया शेयर | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 233.25M | 0.99% |
| 2025 | 230.96M | 6.43% |
| 2024 | 217.00M | 52.04% |
| 2023 | 142.73M | 3.35% |
| 2022 | 138.10M | -4.67% |
| 2021 | 144.87M | 0.15% |
| 2020 | 144.65M | 0.14% |
| 2019 | 144.44M | -0.05% |
| 2018 | 144.52M | 0.11% |
| 2017 | 144.35M | 0.26% |
| 2016 | 143.98M | 2.91% |
| 2015 | 139.90M | 2.76% |
| 2014 | 136.14M | -0.01% |
| 2013 | 136.16M | -0.96% |
| 2012 | 137.49M | -0.65% |
| 2011 | 138.39M | 4.84% |
| 2010 | 132.00M | 8.34% |
| 2009 | 121.83M | 3.78% |
| 2008 | 117.40M | 1,578.29% |
| 2007 | 7.00M | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए बकाया शेयर
| कंपनी | बकाया शेयर | अंतर | देश |
|---|---|---|---|
| 253.90M | 8.86% |
US
|
|
| 396.00M | 69.78% |
US
|
|
| 478.91M | 105.33% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -73.34% |
NL
|
